Michael Lark, Phd Email & Phone Number

Philadelphia, PA, US

Philadelphia, Pennsylvania, United States

Advise the company on both drug development and corporate strategy.

Rochester, New York, United States

Advise the Empire Discovery Institute on drug discovery projects and platforms for transitioning from academia toward commercialization. Lead projects through leveraging both CRO and academic partner capabilities.

Philadelphia, Pennsylvania, United States

Advise the Moulder Center for Drug Discovery Research at Temple University on its strategic direction.

Bethlehem, Pennsylvania, United States

Radnor, PA

As Entrepreneur in Residence at BioAdvance I participate in outreach to research institutions in the mid-Atlantic region to identify scientific opportunities that could be matured into companies, through a relationship with BioAdvance. I also participate in discussions around potential investment decisions and assist BioAdvance portfolio companies as needed.

Berwyn, PA

• Offer expert opinion on assets and programs to assist with investment decisions
• Assist biotech companies identify targets and strategies for rapid value creation
• Generate and execute on plans to deliver data for quick decision making to progress drug discovery and development programs
• Manage network of drug discovery, non-clinical development, regulatory, CMC and project management contributors to aggressively move programs forward

King Of Prussia, Pennsylvania, United States

Consult with CEO to identify and advance novel pain therapetics to key value inflection points. Responsible for setting R&D strategy and executing on plans to progress asset development. Partner with CEO and Board on both dilutive and non-dilutive fund raisning activities for the company.

Philadelphia, Pennsylvania, United States

Participate as a member of the BioMotiv Leadership Team responsible for setting corporate strategy, executing on operational plans, managing budgets and headcount, and assisting with financing for the BioMotiv portfolio. As Executive in Residence, Koutif, I am responsible for oversight of the R&D and financing activities for the company.

Berwyn, Pennsylvania, United States

Led a variety of diligence projects for new project starts. Participated on committees to evaluate progress of ongoing BioMotiv programs and strategic options.

Chesterbrook, PA

Trevena is a commercial stage biopharmaceutical company focused on the discovery and development of novel differentiated products using our proprietary G protein coupled receptor drug discovery platform. As a member of the executive team, I was responsible for development and execution of Trevena's corporate strategy. I played a key role in our private.

Head of Biology Research which included Immunology, Oncology, Cardiovascular and Metabolic Diseases, and Infectious Diseases. Was responsible for the setting and executing on the biology strategy as well as managing the drug discovery portfolio.

Established the Cardiovascular and Metabolic Diseases drug discovery department and built internal capabilities as well as a drug discovery portfolio. Advanced two compounds from discovery into preclinical development. Managed an external partnered project targeting stem cells for the treatment of cardiac diseases. Was a member of the scientific advisory.

Responsible for the management and leadership of the Musculoskelatal Diseases Department with a portfolio of targets for the treatment of osteoporosis and osteoarthritis. Several of these projects, including the cathepsin K and vitronectin receptor antagonist projects generated clinical candidates.

Led and managed the activities in the Bone and Cartilage Biology Department responsible for discoverying therapeutics for the treatment of osteoporosis, osteoarthritis, inflammatory joint diseases and dermatological indications. Built internal capabilities to target osteoarthritis and initiated several osteoarthritis targeted drug discovery programs..

Built research capabilities to target osteoarthritis. Initiated and led a drug discovery program targeted matrix metalloproteinase 3 for the treatment of arthritis. Support both the 5-alpha reductase and TNF-alpha drug discovery programs. Managed a laboratory of 6 MS/BS level reserach associates.